PubMed Health⌕ Search

PubMed · 16173290

Falls in elderly.

Abstract

Falls are a major health problem among the elderly and an estimated 6% of falls by elderly result in fractures. Early identification of fall risk is likely to result in earlier implementation of intervention and to minimise development of secondary problems such as reduced confidence and activity levels. A comprehensive falls risk factor assessment should be performed for older people who present for medical attention after a fall, those who had more than one fall in the preceding year or those who have abnormalities of gait or balance. Falls are as a result of extrinsic risk factors, intrinsic risk factor or a combination of both. Syncope is defined as a transient, self limited loss of consciousness usually leading to a fall. Syncope and falls are often considered two separate entities with different aetiologies. Disorders affecting balance in the elderly are cerebral, cerebellar, spinal cord disorders; dementia; arrhythmias; postural hypotension; cerebrovascular disease; musculoskeletal/orthopaedic disorders; intervertebral disc disorders; psychological factors; visual impairment. Effective interventions include: (1) Health promotion and falls prevention. (2) Single interventions. (3) Medication review. (4) Exercise. (5) Home modifications. (6) To improve safety in the home. (7) To improve safety outside the home. Effective preventive strategies require better understanding of the causes of and risk factors for falling among elderly.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C P Das, S Joseph. 2005. Falls in elderly.. https://pubmed.ncbi.nlm.nih.gov/16173290/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them.

Currently available results from fracture trials provide evidence that the most potent anti-resorptive agents reduce vertebral and non-vertebral fractures maximally by 61% and 51%, respectively. Results from the Phase III trial with denosumab, the human monoclonal antibody, are eagerly awaited. Denosumab leads to sustained 80-90% reduction of bone resorption markers, which is below the level commonly achieved with bisphosphonates, and it will be interesting to see whether this leads to an improvement in its anti-fracture efficacy over bisphosphonates. If the majority of the anti-fracture efficacy of anti-resorptive agents results from the reduction of the remodelling space (removal of stress raisers) and the conservation of structural integrity of cancellous bone, a further decrease in bone resorption might not be desirable, especially as suppression of the residual remodelling capacity could lead to an increased risk for accumulation of microdamage. In contrast to anti-resorptive agents, the bone anabolic parathyroid hormone activates modelling drifts, which act to increase trabecular thickness and add bone predominantly on the endocortical, and to a lesser degree the periosteal, surface. Despite its anabolic nature, reduction of vertebral and non-vertebral fractures is only marginally better than those achieved with anti-resorptive agents. Ageing compromises locomotor capacity and is associated with an increased risk of falls. Perhaps it is time to shift our attendance to the age-related deterioration of muscle or neuromuscular function as a target and add this 'adjuvant therapy' to the potent anti-remodelling and bone anabolic agents available for the treatment of osteoporosis if we truly want to reduce fracture incidence beyond what is possible today.

Accidental Falls↗

Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation.

OBJECTIVES: To determine whether vitamin D supplementation reduces the risk of fracture or falls in elderly people in care home accommodation. DESIGN: A randomised controlled trial of cluster design. SETTING AND SUBJECTS: 223 Residential units (mainly identical 30-bedded units), within 118 homes for elderly people throughout Britain, with 3,717 participating residents (76% women, average age 85 years). The units provided mainly or entirely residential care (35% of residents), nursing care (42%) or care for elderly mentally infirm (EMI) residents (23%). METHODS: Participants were randomly allocated by residential unit (cluster design) to a treated group offered ergocalciferol 2.5 mg every 3 months (equivalent to a daily dose of 1,100 IU), or to a control group. Fractures were reported by staff and confirmed in hospital, and routinely collected data on reported falls were obtained. RESULTS: After median follow-up of 10 months (interquartile range 7-14 months), 64 (3.6%) of 1,762 vitamin D-treated residents and 51 (2.6%) of 1,955 controls had one or more non-vertebral fractures, and 24 (1.3%) and 20 (1.0%), respectively, had a hip fracture. The proportion reporting at least one fall was 44% in vitamin D-treated and 43% in control residents. The differences between the vitamin D and control groups were not statistically significant. The incidence of all non-vertebral fractures in the care homes (3.2% per year) and of hip fractures (1.1% per year) was low, similar to rates in elderly people in sheltered accommodation, and the pre-treatment serum 25-hydroxy vitamin D concentration was high [median 47 nmol/l, measured in a 1% (n = 18) sample]. CONCLUSIONS: We found no evidence that vitamin D prevents fractures or falls in elderly people in care home accommodation.

Accidental Falls↗